

NEXT GENERATION CANCER DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS



BIO081B
August 2014

John Bergin
Project Analyst

ISBN: 1-56965-911-7



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	2
SCOPE AND FORMAT	3
METHODOLOGY	3
INFORMATION SOURCES	4
RELATED BCC RESEARCH REPORTS	4
ANALYST'S CREDENTIALS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, 2013-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
<i>TABLE 1 REPORT SCOPE</i>	11
NEXT GENERATION CANCER DIAGNOSTIC MARKETING POTENTIAL	12
<i>TABLE 2 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	12
DRIVING FORCES	13
<i>TABLE 3 CANCER DIAGNOSTIC MARKET DRIVING FORCES, THROUGH 2019</i>	13
PLATFORMS	14
PRODUCT LIFECYCLE STATUS	15
<i>TABLE 4 DIAGNOSTIC PRODUCT LIFECYCLE STATUS, 2014</i>	15
INDUSTRY	16
<i>TABLE 5 NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY, 2014</i>	16
CHAPTER 4 NEXT GENERATION CANCER DIAGNOSTIC TECHNOLOGIES	19
DIAGNOSTICS OVERVIEW	19
<i>TABLE 6 DIAGNOSTIC MARKET SEGMENTS</i>	19
<i>TABLE 7 NEXT GENERATION CANCER DIAGNOSTIC PLATFORMS, 2014-2019</i>	20
TECHNOLOGY OVERVIEW	20
<i>TABLE 8 ANALYSIS PLATFORMS AND BIOMARKER TYPES</i>	20
GENETIC ANALYSIS	21
<i>FIGURE 1 DNA, MRNA AND GENETIC VARIATION</i>	21
GENETIC ANALYSIS TECHNOLOGIES	23
<i>TABLE 9 SCOPE OF KEY GENOMIC ANALYSIS TECHNOLOGIES, 2014</i>	23
<i>TABLE 10 GENETIC ANALYSIS TECHNOLOGY PLATFORM COMPARISON</i>	25
EPIGENETIC ANALYSIS	26
PARADIGM CHANGE	26
<i>TABLE 11 EPIGENETICS WITHIN THE MOLECULAR BIOLOGY PARADIGM</i>	27

TOPIC	PAGE NO.
DNA METHYLATION ANALYSIS	27
<i>FIGURE 2 EPIGENETIC CHANGES TO DNA AFFECTING GENE EXPRESSION</i>	28
CIRCULATING TUMOR CELL ANALYSIS	28
<i>TABLE 12 CIRCULATING TUMOR CAPTURE METHODS</i>	29
<i>TABLE 13 CIRCULATING TUMOR CAPTURE IDENTIFICATION METHODS</i>	30
PROTEOMIC ANALYSIS	30
NEXT GENERATION CANCER DIAGNOSTIC TECHNOLOGY PLATFORMS	31
DNA MICROARRAYS	31
<i>TABLE 14 DNA MICROARRAY TECHNOLOGIES</i>	31
PROTEIN MICROARRAYS	32
<i>TABLE 15 PROTEIN MICROARRAY PLATFORMS</i>	32
LAB-ON-A-CHIP	33
<i>TABLE 16 LAB-ON-A-CHIP TYPES</i>	34
In Vitro Proteomics	34
Electrophoresis on a Chip	34
Structural Proteomics	35
PCR on a Chip	35
Immunoassays on a Chip	36
REAL-TIME POLYMERASE CHAIN REACTION	36
<i>TABLE 17 CONVENTIONAL END-POINT REAL-TIME POLYMERASE CHAIN REACTION DETECTION PROBLEMS</i>	37
<i>TABLE 18 REAL-TIME POLYMERASE CHAIN REACTION CANCER DIAGNOSTIC APPLICATIONS</i>	38
NEXT GENERATION SEQUENCING PLATFORMS	38
<i>TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES</i>	38
<i>TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW, 2014</i>	38
<i>TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW, 2014</i>	40
<i>TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW, 2014</i>	41
BENCHTOP SEQUENCERS	41
<i>TABLE 23 BENCHTOP SEQUENCER PLATFORMS, 2014</i>	42
NEXT GENERATION SEQUENCING IN THE CLINICAL SETTING	43
<i>TABLE 24 GENETIC TESTING EVOLUTION</i>	43
<i>TABLE 25 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION SEQUENCING DIAGNOSTICS, 2014-2019</i>	44
CHAPTER 5 NEXT GENERATION CANCER DIAGNOSTIC APPLICATIONS	47
INTRODUCTION	47
<i>TABLE 26 NEXT GENERATION DIAGNOSTIC PARADIGM SHIFT, 2000-2020</i>	47
BIOMARKER DISCOVERY DRIVING GROWTH	48
<i>TABLE 27 BIOMARKERS USED IN NEXT GENERATION DIAGNOSTICS</i>	48
CLINICAL ACCEPTANCE OF A NEW DIAGNOSTIC ASSAY	50
<i>TABLE 28 DNA MICROARRAY DIAGNOSTIC TEST ADOPTION RATE</i>	50
MOLECULAR DIAGNOSTICS	51
INTRODUCTION	51
MARKET PENETRATION CHALLENGES	52
<i>TABLE 29 COMPARISON OF DNA-BASED MDX PLATFORMS</i>	53

TOPIC	PAGE NO.
<i>TABLE 30 FACTORS AFFECTING PENETRATION OF NEXT GENERATION FORMATS INTO THE MDX MARKET</i>	54
MARKET SEGMENTS	56
TEST SENSITIVITY AND SPECIFICITY	57
<i>FIGURE 3 SENSITIVITY AND SPECIFICITY</i>	57
REGULATORY STATUS	58
STATUS OF NEXT GENERATION DIAGNOSTICS BY INDICATION	60
CANCER OVERVIEW	60
<i>TABLE 31 U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013 (NUMBER)</i>	60
BLADDER CANCER	61
<i>TABLE 32 BLADDER CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014</i>	61
BRAIN CANCER	62
<i>TABLE 33 BRAIN CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014</i>	62
BREAST CANCER	63
Breast Cancer Screening	63
Prognosis and Pharmacogenetics Tests	64
<i>TABLE 34 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY CANCER CLASSIFICATION, 2014 (NUMBER)</i>	65
Breast Cancer MDx Platforms	65
<i>TABLE 35 BREAST CANCER MDX TECHNOLOGY PLATFORMS, 2014</i>	66
Status of Next generation Breast Cancer Tests	67
<i>TABLE 36 NEXT GENERATION BREAST CANCER TESTS, 2014</i>	67
Breast Cancer Early Detection and Screening Tests	69
Breast Cancer Risk Tests	69
Response to Chemotherapy, Recurrence Probability and Subtyping	70
CERVICAL CANCER	73
<i>TABLE 37 NEXT GENERATION HUMAN PAPILLOMA VIRUS AND CERVICAL CANCER TESTS, 2014</i>	75
COLORECTAL CANCER	78
Conventional Colorectal Cancer Screening Tests	78
<i>TABLE 38 COLORECTAL CANCER SCREENING AND DIAGNOSTIC TESTS, 2014</i>	79
Next Generation Colorectal Cancer Diagnostics Tests	80
<i>TABLE 39 NEXT GENERATION DIAGNOSTIC TESTS FOR COLORECTAL CANCER, 2014</i>	80
CANCER OF UNKNOWN PRIMARY	84
<i>TABLE 40 CANCER OF UNKNOWN PRIMARY NEXT GENERATION DIAGNOSTIC TESTS, 2014</i>	85
GASTRIC CANCER	87
<i>TABLE 41 GASTRIC AND STOMACH CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014</i>	87
KIDNEY CANCER	88
<i>TABLE 42 NEXT GENERATION KIDNEY CANCER DIAGNOSTIC TESTS, 2014</i>	88
LEUKEMIA	89
<i>TABLE 43 NEXT GENERATION LEUKEMIA AND MYELOMA DIAGNOSTIC TESTS, 2014</i>	89
LIVER CANCER	93
<i>TABLE 44 NEXT GENERATION LIVER CANCER DIAGNOSTIC TESTS, 2014</i>	93
LUNG CANCER	94

TOPIC	PAGE NO.
<i>TABLE 45 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER, 2014 (%)</i>	94
<i>TABLE 46 NEXT GENERATION LUNG CANCER DIAGNOSTIC TESTS, 2014</i>	95
LYMPHOMAS	98
<i>TABLE 47 NEXT GENERATION LYMPHOMA CANCER DIAGNOSTIC TESTS, 2014</i>	98
MELANOMA	99
<i>TABLE 48 NEXT GENERATION MELANOMA DIAGNOSTIC TESTS, 2014</i>	100
OVARIAN CANCER	101
<i>TABLE 49 OVARIAN CANCER EARLY SCREENING TESTS</i>	101
<i>TABLE 50 NEXT GENERATION OVARIAN CANCER DIAGNOSTIC TESTS, 2014</i>	103
PAN-CANCER	105
<i>TABLE 51 NEXT GENERATION PAN-CANCER DIAGNOSTIC TESTS, 2014</i>	105
PANCREATIC CANCER	108
<i>TABLE 52 NEXT GENERATION PANCREATIC CANCER DIAGNOSTIC TESTS, 2014</i>	108
PROSTATE CANCER	109
<i>TABLE 53 NEXT GENERATION PROSTATE CANCER DIAGNOSTIC TESTS, 2014</i>	109
THYROID CANCER	112
<i>TABLE 54 NEXT GENERATION THYROID CANCER DIAGNOSTIC TESTS, 2014</i>	113
NEXT GENERATION CANCER DIAGNOSTIC TEST SUMMARY	114
<i>TABLE 55 NEXT GENERATION DIAGNOSTIC TEST SUMMARY BY INDICATION AND TECHNOLOGY, 2014</i>	114
CHAPTER 6 INDUSTRY DYNAMICS	117
ACQUISITIONS	117
<i>TABLE 56 ACQUISITIONS IN NEXT GENERATION CANCER DIAGNOSTICS INDUSTRY, 2012-2014</i>	117
STRATEGIC ALLIANCES	118
<i>TABLE 57 NEXT GENERATION CANCER DIAGNOSTIC STRATEGIC ALLIANCES, 2012-2014</i>	119
CIRCULATING TUMOR CELL DIAGNOSTIC INDUSTRY	124
<i>TABLE 58 CIRCULATING TUMOR CELL INDUSTRY, 2014</i>	124
DNA MICROARRAY DIAGNOSTIC INDUSTRY	129
<i>TABLE 59 DNA MICROARRAY INDUSTRY, 2014</i>	130
NEXT GENERATION SEQUENCING INSTRUMENT INDUSTRY	131
<i>TABLE 60 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE, 2014</i>	131
CLINICAL LABORATORY NEXT GENERATION SEQUENCING INDUSTRY	133
<i>TABLE 61 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS LABORATORIES WITH NEXT-GENERATION SEQUENCING DIAGNOSTICS, 2014</i>	133
LAB-ON-A-CHIP NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY	135
<i>TABLE 62 NEXT GENERATION LAB-ON-A-CHIP CANCER DIAGNOSTIC INDUSTRY, 2014</i>	135
RT-PCR NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY	137
<i>TABLE 63 NEXT GENERATION RT-PCR CANCER DIAGNOSTIC INDUSTRY, 2014</i>	137
CHAPTER 7 NEXT GENERATION CANCER DIAGNOSTIC MARKETS	140
INDUSTRY GROWTH DRIVING FORCES	140
<i>TABLE 64 CANCER DIAGNOSTIC MARKET DRIVING FORCES, 2014-2019</i>	140
LIFE SCIENCE RESEARCH AND DEVELOPMENT FUNDING GROWTH	140

TOPIC	PAGE NO.
TARGETED MEDICINE DEVELOPMENT	141
EARLY CANCER DETECTION DEMAND	141
AGING POPULATIONS IN DEVELOPED REGIONS OF THE WORLD	142
INNOVATIVE DIAGNOSTIC TESTING FORMAT DEMAND	142
ONGOING DISCOVERIES IN GENOMICS	142
GENE AND SINGLE NUCLEOTIDE POLYMORPHISM DISEASE ASSOCIATION DISCOVERY	142
MARKET SUMMARY	143
MARKET BY TECHNOLOGY PLATFORM	143
<i>TABLE 65 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	143
MARKET BY ANALYSIS TYPE	144
<i>TABLE 66 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY ANALYSIS TYPE, THROUGH 2019 (\$ MILLIONS)</i>	144
MARKET BY INDICATION	145
<i>TABLE 67 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	145
Bladder Cancer	146
Brain Cancer	146
Breast Cancer	147
Cervical Cancer	147
Colorectal Cancer	148
Cancer of Unknown Primary	148
Gastric Cancer	148
Kidney Cancer	149
Leukemia	150
Liver Cancer	150
Lung Cancer	151
Lymphoma	151
Melanoma	152
Ovarian Cancer	152
Pan-Cancer	153
Pancreatic Cancer	154
Prostate Cancer	154
Thyroid Cancer	155
MARKET BY DIAGNOSTIC FUNCTION	155
<i>TABLE 68 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY FUNCTION, THROUGH 2019 (\$ MILLIONS)</i>	155
MARKETS BY TECHNOLOGY FORMAT	156
DNA MICROARRAY MARKET	156
<i>TABLE 69 GLOBAL DNA MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	156
PROTEIN MICROARRAY MARKET	158
<i>TABLE 70 GLOBAL PROTEIN MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	158
LAB-ON-A-CHIP MARKET	159
<i>TABLE 71 GLOBAL LAB-ON-A-CHIP CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	159
RT-PCR MARKET	160

TOPIC	PAGE NO.
<i>TABLE 72 GLOBAL RT-PCR CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	160
NEXT GENERATION SEQUENCING MARKET	162
<i>TABLE 73 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	162
NEXT GENERATION CAPTURE MARKET	163
<i>TABLE 74 GLOBAL NEXT GENERATION CAPTURE CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	164
MULTIPLEX CONVENTIONAL MARKET	165
<i>TABLE 75 GLOBAL MULTIPLEX CONVENTIONAL CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	165
MARKETS BY DIAGNOSTIC FUNCTION	166
RISK MARKET	166
<i>TABLE 76 GLOBAL NEXT GENERATION CANCER RISK MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	166
SCREENING MARKET	167
<i>TABLE 77 GLOBAL NEXT GENERATION CANCER SCREENING MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	167
PROGNOSTIC MARKET	168
<i>TABLE 78 GLOBAL NEXT GENERATION CANCER PROGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	169
MONITORING MARKET	170
<i>TABLE 79 GLOBAL NEXT GENERATION CANCER MONITORING MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	170
COMPANION DIAGNOSTIC MARKET	171
<i>TABLE 80 GLOBAL NEXT GENERATION CANCER COMPANION DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	172
MARKETS FOR KEY INDICATIONS BY TECHNOLOGY PLATFORM	172
BREAST CANCER MARKET	172
<i>TABLE 81 GLOBAL NEXT GENERATION BREAST CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	173
CERVICAL CANCER MARKET	174
<i>TABLE 82 GLOBAL NEXT GENERATION CERVICAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	174
COLORECTAL CANCER MARKET	174
<i>TABLE 83 GLOBAL NEXT GENERATION COLORECTAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	175
CANCER OF UNKNOWN PRIMARY (CUP) MARKET	175
<i>TABLE 84 GLOBAL NEXT GENERATION CANCER OF UNKNOWN PRIMARY (CUP) DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	176
LEUKEMIA MARKET	176
<i>TABLE 85 GLOBAL NEXT GENERATION LEUKEMIA DIAGNOSTIC MARKET BY TECHNOLOGY FORMAT, THROUGH 2015 (\$ MILLIONS)</i>	177
LUNG CANCER MARKET	178
<i>TABLE 86 GLOBAL NEXT GENERATION LUNG CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	178
LYMPHOMA MARKET	179
<i>TABLE 87 GLOBAL NEXT GENERATION LYMPHOMA DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	179
PAN-CANCER MARKET	179

TOPIC	PAGE NO.
<i>TABLE 88 GLOBAL NEXT GENERATION PAN-CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	180
<i>TABLE 89 GENOME COVERAGE OF REPRESENTATIVE NEXT GENERATION SEQUENCING PAN-CANCER TESTS, 2014</i>	180
PROSTATE CANCER MARKET	181
<i>TABLE 90 GLOBAL NEXT GENERATION PROSTATE CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)</i>	181
NEXT GENERATION CANCER DIAGNOSTIC REGIONAL MARKET	182
<i>TABLE 91 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	182
CHAPTER 8 PATENTS	185
MICROARRAY PATENTS	185
<i>TABLE 92 DNA MICROARRAY-RELATED PATENTS BY REGION, 2002-2012</i>	185
<i>TABLE 93 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012</i>	186
LAB-ON-A-CHIP PATENTS	186
<i>TABLE 94 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012</i>	187
RT-PCR PATENTS	187
<i>TABLE 95 ISSUED RT-PCR-RELATED PATENTS BY REGION, 2002-2012</i>	188
CIRCULATING TUMOR CELL PATENTS	188
<i>TABLE 96 ISSUED CIRCULATING TUMOR CELL-RELATED PATENTS BY REGION, 2002-2012</i>	188
CLINICAL NEXT GENERATION SEQUENCING PATENTS	189
<i>TABLE 97 CLINICAL NEXT GENERATION SEQUENCING-RELATED SEQUENCING PATENTS, 2002-2012</i>	189
CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION	189
<i>TABLE 98 CLINICAL NEXT GENERATION SEQUENCING-RELATED PATENTS BY INDICATION, 2002-2012</i>	190
CHAPTER 9 COMPANY PROFILES	192
20/20 GENE SYSTEMS INC.	192
ABBOTT LABORATORIES	193
ABTECH SCIENTIFIC INC.	193
ADAPTIVE BIOTECHNOLOGIES INC.	194
ADNAGEN GMBH	195
ADVANCED CELL DIAGNOSTICS INC.	195
AFFYMETRIX INC.	195
AGENDIA NV	197
<i>TABLE 99 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE, 2014</i>	198
AGILENT TECHNOLOGIES INC.	199
ALLEGRO DIAGNOSTICS INC.	200
ALMAC GROUP LTD.	201
AMBRY GENETICS	202
APPISTRY INC.	203
ARPEGGI INC.	203
ARRAYIT CORP.	204
ASTRID BIOSCIENCE GMBH	204
ASURAGEN INC.	205
AUTOGENOMICS INC.	205

TOPIC	PAGE NO.
AXELA BIOSENSORS	205
AYANDA BIOSYSTEMS SA	206
BGI	207
BIOCARTIS SA	208
BIOCEPT INC.	209
<i>TABLE 100 CANCERS</i>	209
BIODESIX INC.	210
BIOLOGICAL DYNAMICS INC.	210
BIOETHERANOSTICS	211
BIOTIME INC.	212
BOREAL GENOMICS	212
CANCER GENETICS INC.	213
CARIS LIFE SCIENCES	214
CASTLE BIOSCIENCES INC.	215
CEPHEID	215
CHRONIX BIOMEDICAL INC.	216
CIRCADIAN TECHNOLOGIES	216
COMBIMATRIX MOLECULAR DIAGNOSTICS INC.	217
CVERGENX	218
DECODE GENETICS	218
DIAGNOPLEX SA	219
DIAXONHIT	219
EPIC SCIENCES INC.	220
EXACT SCIENCES CORP.	220
EXIQON A/S	221
EXOSOME SCIENCES INC.	221
EXOSOME DIAGNOSTICS INC.	222
EVENTUS DIAGNOSTICS INC.	222
FOUNDATION MEDICINE	223
FUSION GENOMICS CORP.	224
GATC BIOTECH AG	225
GE HEALTHCARE	225
GENALYTE INC.	226
GENEDX INC.	226
GENENEWS	227
GENERA BIOSYSTEMS LIMITED	228
GENETIC TECHNOLOGIES LTD.	229
GENOMIC HEALTH INC.	229
GIGAGEN INC.	230
GUARDANT HEALTH INC.	231
HEALTHLINX LIMITED	231
HOLOGIC INC.	232
HUMAN LONGEVITY INC.	233
ILLUMINA INC.	233
INSIGHT GENETICS INC.	236
INTEGRAGEN SA	237
INVITAE	237

TOPIC	PAGE NO.
IRIS BIOTECHNOLOGIES INC.	238
IRIS INTERNATIONAL INC.	238
JOHNSON & JOHNSON	239
LABORATORY CORP. OF AMERICA INC.	239
LABORATORY FOR MOLECULAR MEDICINE	240
LIFE TECHNOLOGIES INC.	241
MAGARRAY INC.	243
MAVEN BIOTECHNOLOGIES	243
MD ANDERSON CANCER CENTER	243
MDX HEALTH S.A.	244
MED BIOGENE INC.	244
MEDGENOME LABS PVT. LTD.	245
METAMARK GENETICS INC.	245
MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD.	245
MIRA DX	246
MITOMICS INC.	246
MYRIAD GENETICS INC.	247
NANOIVD INC.	248
NANOSTRING TECHNOLOGIES INC.	248
NATURALNANO INC.	249
NEOGENOMICS LABORATORIES	249
NEWGENE LIMITED	249
<i>TABLE 101 NEWGENE CANCER TESTS</i>	250
NEXUS DX INC.	251
NOVARTIS AG	251
NUCLEA BIOTECHNOLOGIES INC.	252
NUVERA BIOSCIENCES	252
ONCODNA SA	253
ONCOLYS BIOPHARMA INC.	253
ONCOSPIRE GENOMICS	254
OPKO HEALTH INC.	254
OXFORD GENE TECHNOLOGY	255
PARADIGM	256
PERKIN ELMER INC.	256
PERSONAL GENOME DIAGNOSTICS	259
PGXL LABORATORIES	259
PHILIPS ELECTRONICS NV	260
PHYSICIAN'S CHOICE LABORATORY SERVICES	260
PREVENTIONGENETICS INC.	260
QIAGEN	261
QIAGEN MARSEILLE	262
QUANTUMDX	263
QUEST DIAGNOSTICS	264
RAINDANCE TECHNOLOGIES INC.	265
RANDOX LABORATORIES, LTD.	267
RESPONSE GENETICS INC.	267
RHEONIX	268

TOPIC	PAGE NO.
ROCHE HOLDING AG	268
ROSETTA GENOMICS INC.	269
<i>TABLE 102 ROSETTA'S DIAGNOSTIC TESTS, 2014</i>	269
SEQUENTA INC.	271
SIGNAL GENETICS LLC	272
SIGNATURE DIAGNOSTICS AG	273
SISTEMAS GENOMICOS, SL	274
SKYLINEDX B.V.	274
SOFTGENETICS LLC	275
SOMALOGIC INC.	275
STRAND LIFE SCIENCES	276
SYAPSE	276
SYSMEX CORP.	277
THERMO FISHER SCIENTIFIC INC.	277
TRANSGENOMIC INC.	278
TROVAGENE INC.	279
VERACYTE	280
VERISANTE TECHNOLOGY INC.	281
VITATEX INC.	282
VOLITIONRX LTD.	282
XAGENIC INC.	283

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 REPORT SCOPE	11
TABLE 2 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	12
TABLE 3 CANCER DIAGNOSTIC MARKET DRIVING FORCES, THROUGH 2019	13
TABLE 4 DIAGNOSTIC PRODUCT LIFECYCLE STATUS, 2014	15
TABLE 5 NEXT GENERATION CANCER DIAGNOSTIC INDUSTRY, 2014	16
TABLE 6 DIAGNOSTIC MARKET SEGMENTS	19
TABLE 7 NEXT GENERATION CANCER DIAGNOSTIC PLATFORMS, 2014-2019	20
TABLE 8 ANALYSIS PLATFORMS AND BIOMARKER TYPES	20
TABLE 9 SCOPE OF KEY GENOMIC ANALYSIS TECHNOLOGIES, 2014	23
TABLE 10 GENETIC ANALYSIS TECHNOLOGY PLATFORM COMPARISON	25
TABLE 11 EPIGENETICS WITHIN THE MOLECULAR BIOLOGY PARADIGM	27
TABLE 12 CIRCULATING TUMOR CAPTURE METHODS	29
TABLE 13 CIRCULATING TUMOR CAPTURE IDENTIFICATION METHODS	30
TABLE 14 DNA MICROARRAY TECHNOLOGIES	31
TABLE 15 PROTEIN MICROARRAY PLATFORMS	32
TABLE 16 LAB-ON-A-CHIP TYPES	34
TABLE 17 CONVENTIONAL END-POINT REAL-TIME POLYMERASE CHAIN REACTION DETECTION PROBLEMS	37
TABLE 18 REAL-TIME POLYMERASE CHAIN REACTION CANCER DIAGNOSTIC APPLICATIONS	38
TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES	38
TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW, 2014	38
TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW, 2014	40
TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW, 2014	41
TABLE 23 BENCHTOP SEQUENCER PLATFORMS, 2014	42
TABLE 24 GENETIC TESTING EVOLUTION	43
TABLE 25 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION SEQUENCING DIAGNOSTICS, 2014-2019	44
TABLE 26 NEXT GENERATION DIAGNOSTIC PARADIGM SHIFT, 2000-2020	47
TABLE 27 BIOMARKERS USED IN NEXT GENERATION DIAGNOSTICS	48
TABLE 28 DNA MICROARRAY DIAGNOSTIC TEST ADOPTION RATE	50
TABLE 29 COMPARISON OF DNA-BASED MDX PLATFORMS	53
TABLE 30 FACTORS AFFECTING PENETRATION OF NEXT GENERATION FORMATS INTO THE MDX MARKET	54
TABLE 31 U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013 (NUMBER)	60
TABLE 32 BLADDER CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014	61
TABLE 33 BRAIN CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014	62
TABLE 34 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY CANCER CLASSIFICATION, 2014 (NUMBER)	65
TABLE 35 BREAST CANCER MDX TECHNOLOGY PLATFORMS, 2014	66
TABLE 36 NEXT GENERATION BREAST CANCER TESTS, 2014	67
TABLE 37 NEXT GENERATION HUMAN PAPILLOMA VIRUS AND CERVICAL CANCER TESTS, 2014	75
TABLE 38 COLORECTAL CANCER SCREENING AND DIAGNOSTIC TESTS, 2014	79

TABLE HEADING	PAGE NO.
TABLE 39 NEXT GENERATION DIAGNOSTIC TESTS FOR COLORECTAL CANCER, 2014	80
TABLE 40 CANCER OF UNKNOWN PRIMARY NEXT GENERATION DIAGNOSTIC TESTS, 2014	85
TABLE 41 GASTRIC AND STOMACH CANCER NEXT GENERATION DIAGNOSTIC TESTS, 2014	87
TABLE 42 NEXT GENERATION KIDNEY CANCER DIAGNOSTIC TESTS, 2014	88
TABLE 43 NEXT GENERATION LEUKEMIA AND MYELOMA DIAGNOSTIC TESTS, 2014	89
TABLE 44 NEXT GENERATION LIVER CANCER DIAGNOSTIC TESTS, 2014	93
TABLE 45 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER, 2014 (%)	94
TABLE 46 NEXT GENERATION LUNG CANCER DIAGNOSTIC TESTS, 2014	95
TABLE 47 NEXT GENERATION LYMPHOMA CANCER DIAGNOSTIC TESTS, 2014	98
TABLE 48 NEXT GENERATION MELANOMA DIAGNOSTIC TESTS, 2014	100
TABLE 49 OVARIAN CANCER EARLY SCREENING TESTS	101
TABLE 50 NEXT GENERATION OVARIAN CANCER DIAGNOSTIC TESTS, 2014	103
TABLE 51 NEXT GENERATION PAN-CANCER DIAGNOSTIC TESTS, 2014	105
TABLE 52 NEXT GENERATION PANCREATIC CANCER DIAGNOSTIC TESTS, 2014	108
TABLE 53 NEXT GENERATION PROSTATE CANCER DIAGNOSTIC TESTS, 2014	109
TABLE 54 NEXT GENERATION THYROID CANCER DIAGNOSTIC TESTS, 2014	113
TABLE 55 NEXT GENERATION DIAGNOSTIC TEST SUMMARY BY INDICATION AND TECHNOLOGY, 2014	114
TABLE 56 ACQUISITIONS IN NEXT GENERATION CANCER DIAGNOSTICS INDUSTRY, 2012-2014	117
TABLE 57 NEXT GENERATION CANCER DIAGNOSTIC STRATEGIC ALLIANCES, 2012-2014	119
TABLE 58 CIRCULATING TUMOR CELL INDUSTRY, 2014	124
TABLE 59 DNA MICROARRAY INDUSTRY, 2014	130
TABLE 60 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE, 2014	131
TABLE 61 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS LABORATORIES WITH NEXT-GENERATION SEQUENCING DIAGNOSTICS, 2014	133
TABLE 62 NEXT GENERATION LAB-ON-A-CHIP CANCER DIAGNOSTIC INDUSTRY, 2014	135
TABLE 63 NEXT GENERATION RT-PCR CANCER DIAGNOSTIC INDUSTRY, 2014	137
TABLE 64 CANCER DIAGNOSTIC MARKET DRIVING FORCES, 2014-2019	140
TABLE 65 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	143
TABLE 66 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY ANALYSIS TYPE, THROUGH 2019 (\$ MILLIONS)	144
TABLE 67 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	145
TABLE 68 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY FUNCTION, THROUGH 2019 (\$ MILLIONS)	155
TABLE 69 GLOBAL DNA MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	156
TABLE 70 GLOBAL PROTEIN MICROARRAY CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	158
TABLE 71 GLOBAL LAB-ON-A-CHIP CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	159
TABLE 72 GLOBAL RT-PCR CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	160

TABLE HEADING	PAGE NO.
TABLE 73 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	162
TABLE 74 GLOBAL NEXT GENERATION CAPTURE CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	164
TABLE 75 GLOBAL MULTIPLEX CONVENTIONAL CANCER DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	165
TABLE 76 GLOBAL NEXT GENERATION CANCER RISK MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	166
TABLE 77 GLOBAL NEXT GENERATION CANCER SCREENING MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	167
TABLE 78 GLOBAL NEXT GENERATION CANCER PROGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	169
TABLE 79 GLOBAL NEXT GENERATION CANCER MONITORING MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	170
TABLE 80 GLOBAL NEXT GENERATION CANCER COMPANION DIAGNOSTIC MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	172
TABLE 81 GLOBAL NEXT GENERATION BREAST CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	173
TABLE 82 GLOBAL NEXT GENERATION CERVICAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	174
TABLE 83 GLOBAL NEXT GENERATION COLORECTAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	175
TABLE 84 GLOBAL NEXT GENERATION CANCER OF UNKNOWN PRIMARY (CUP) DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	176
TABLE 85 GLOBAL NEXT GENERATION LEUKEMIA DIAGNOSTIC MARKET BY TECHNOLOGY FORMAT, THROUGH 2015 (\$ MILLIONS)	177
TABLE 86 GLOBAL NEXT GENERATION LUNG CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	178
TABLE 87 GLOBAL NEXT GENERATION LYMPHOMA DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	179
TABLE 88 GLOBAL NEXT GENERATION PAN-CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	180
TABLE 89 GENOME COVERAGE OF REPRESENTATIVE NEXT GENERATION SEQUENCING PAN-CANCER TESTS, 2014	180
TABLE 90 GLOBAL NEXT GENERATION PROSTATE CANCER DIAGNOSTIC MARKET BY TECHNOLOGY PLATFORM, THROUGH 2019 (\$ MILLIONS)	181
TABLE 91 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC BY REGION, THROUGH 2019 (\$ MILLIONS)	182
TABLE 92 DNA MICROARRAY-RELATED PATENTS BY REGION, 2002-2012	185
TABLE 93 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012	186
TABLE 94 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012	187
TABLE 95 ISSUED RT-PCR-RELATED PATENTS BY REGION, 2002-2012	188
TABLE 96 ISSUED CIRCULATING TUMOR CELL-RELATED PATENTS BY REGION, 2002-2012	188
TABLE 97 CLINICAL NEXT GENERATION SEQUENCING-RELATED SEQUENCING PATENTS, 2002-2012	189
TABLE 98 CLINICAL NEXT GENERATION SEQUENCING-RELATED PATENTS BY INDICATION, 2002-2012	190
TABLE 99 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE, 2014	198
TABLE 100 CANCERS	209
TABLE 101 NEWGENE CANCER TESTS	250
TABLE 102 ROSETTA'S DIAGNOSTIC TESTS, 2014	269

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET BY INDICATION, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 DNA, MRNA AND GENETIC VARIATION	21
FIGURE 2 EPIGENETIC CHANGES TO DNA AFFECTING GENE EXPRESSION	28
FIGURE 3 SENSITIVITY AND SPECIFICITY	57